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Background: Patients undergoing long-term hemodialysis have a high prevalence of 
Staphylococcus aureus nasal carriage, which may lead to serious infections. Mupirocin 
ointment has been used intranasally to eradicate S. aureus carriage in health human 
volunteers and health care workers. Chlorhexidine, an antiseptic with excellent 
antistaphylococcal activity, is widely used for handwashing and skin cleansing. 
Methods: Anterior nares cultures were obtained from patients older than 18 years who 
were undergoing long-term hemodialysis. Patients with S. aureus nasal carriage were 
enrolled in the study. Axillae and groins were cultured. Patients were given mupirocin 
ointment intranasally twice per day for 7 days and chlorhexidine body scrubs daily for 
the first 3 days. Follow-up cultures were obtained from anterior nares, axillae, and 
groins at 1 day, and 1, 4, 8 and 12 weeks after treatment. 
Results: One day after completion of treatment nasal carriage was eradicated in 83% of 
patients (15 / 18). After 12 weeks, 69% of patients (11 / 16) were free of nasal carriage. 
Conclusions: Success rates of eradication were excellent compared with those in other 
published reports. This simple and effective regimen had no major side effects. (AJIC 
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Staphy lococcus  aureus  is the  most  common 
cause  of  in fec t ion  in  pat ients  undergo ing  long-  
te rm hemodia lys i s .2 ,   S. aureus  may cause  ser ious  
in fec t ions  in these  pat ients ,  inc lud ing  bactere -  
mia ,  endocard i t i s ,  in fec ted  ar ter iovenous  fis- 
tu las  and  shunts ,  and  vascu lar  access  s i te  infec- 
t ions?  s Most  pat ients  undergo ing  long- term 
hemodia lys i s  a re  nasa l  car r ie rs  of  S. aureus.  6, 7 
Al though one  s tudy  repor ted  that  S. aureus  on 
the  vascu lar  access  s i te  appeared  to be  acqu i red  
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from the anterior nares, 8another study reported 
that S. aureus on the skin of vascular access ite 
was associated with poor personal hygiene. 9 It 
seems certain, however, that there is a close re- 
lationship between skin colonization and nasal 
carriage of S. aureus. 
Over the years, eradication of S. aureus nasal 
carriage has been attempted with systemic and 
topical antimicrobial agents, with varying de- 
grees of success. 1° However, nasal recolonization 
of S. aureus is not uncommonly detected on fol- 
low-up. Mupirocin, a recently available topical 
antimicrobial agent, is effective against S. au- 
reus. jl Mupirocin has been used to eradicate S. 
aureus nasal carriage in healthy human volun- 
teers, among the staff of a hospital during an 
outbreak of staphylococcal infections, and 
among residents of a long-term care institu- 
tion. 1214 Chlorhexidine is an antiseptic with ex- 
cellent antistaphylococcal ctivity. It is widely 
used for handwashing and skin cleansing. 
The purpose of this study was to ascertain the 
efficacy of the application of mupirocin ointment 
to the anterior nares, in combination with body- 
scrubs with chlorhexidine, in the eradication of 
S. aureus nasal carriage among patients under- 
going long-term dialysis. 
METHODS 
Patient population 
All patients more than 18 years of age in the 
long-term hemodialysis unit in our hospital were 
asked to participate in this study. Patients who 
had a history of allergy to either mupirocin or 
chlorhexidine were excluded. Written, informed 
consent was obtained after oral explanation. The 
research protocol was approved by the medical 
research committee and the institutional review 
board of the hospital. The nephrologists gave per- 
mission for their patients to participate in this 
study. 
Study design 
Screening of patients. After written, informed 
consent had been obtained, swabs from both an- 
terior nares were obtained for culture. Patients 
whose anterior nares culture grew S. aureus were 
enrolled in this study. For patients whose ante- 
rior nares culture did not grow S. aureus at this 
time, an anterior nares culture was obtained 1 
month later. If this repeated anterior nares cul- 
ture grew S. aureus, the patient was then asked 
to enroll in the study. 
Study protocol. Cultures of the axil lae and 
groins were obtained from all patients whose an- 
terior nares culture grew S. aureus. Demographic 
data were collected. Patients were given 14 pack- 
ets of mupirocin 2% ointment in polyethylene 
glycol base and 14 swab applicators and taught 
how to apply mupirocin to the anterior nares 
twice daily for 7 days. One packet of mupirocin 
ointment and one swab applicator were to be 
used each time and discarded after use. Patients 
were also given three bottles of chlorhexidine so- 
lution (4 fluid ounces each) and instructed to ap- 
ply the solution to the whole body from the neck 
down, especially to the axillae and groins, during 
daily baths for 3 days. One bottle was to be used 
each time. 
Posttreatment cultures of the anterior nares, 
axillae, and groins were taken 1 day, 1 week, 4 
weeks, 8 weeks, and 12 weeks after completion 
of treatment. 
Microbiology. Swabs were streaked on mannitol 
salt agar and incubated at 37 ° C for 48 hours. 
Mannitol-positive colonies were tested for co- 
agulase. Coagulase-positive colonies were des- 
ignated as S. aureus. All S. aureus isolates were 
tested for susceptibil ity to penicillin and oxacil- 
lin by the standard disk diffusion tes ty  
RESULTS 
Sixteen of the 52 patients originally cultured 
were S. aureus nasal carriers. The remaining 36 
patients were cultured again 1 month later; six 
were then found to be S. aureus nasal carriers. 
Twenty-two patients were therefore nrolled in 
the study. 
Diabetes mellitus 
Eight (35%) of the 23 patients with diabetes 
mellitus and 14 (48%) of the 29 patients who did 
not have diabetes mellitus were S. aureus nasal 
carriers. Five (38%) of the 13 patients who were 
receiving insulin therapy and three (30%) of the 
10 patients with diabetes mellitus but not re- 
ceiving insulin therapy were S. aureus nasal 
carriers. 
Length of treatment by hemodialysis 
For thee 22 patients who were S. aureus nasal 
carriers, the duration of hemodialysis treatment 
ranged from 2 to 82 months, with a mean Of 35 
months and median of 37 months. For the 30 
patients who were not S. aureus nasal carriers, 
the durat ion'of  hemodialysis treatment ranged 
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Table 1. Results of mupirocin ointment and chlorhexidine in the treatrhent of S. aureus  carriage 
Posttreatment 
Source of spec imens Pretreatment 1 d* 1 wk 4 wkl" 8 wk 12 wkl" 
Anterior nares 22/22 3/18 3/18 5/17 4/17 5/16 
Axillae 4/22 0/18 0/18 0/17 0/17 0/16 
Groins 8/22 2/18 1/18 2/17 2/17 1/16 
Values are expressed as number of positive cultures/number of patients cultured. 
*Four patients did not complete treatment. 
-IQne patient died. 
from 1 to 58 months, with a mean of 23 months 
and median of 22 months. The difference be- 
tween the two groups is almost statistically sig- 
nificant (p = 0.063, t = 1.95, two-tailed t test). 
S. aureus  carriage 
Results of cultures for S. aureus  are detailed in 
Table 1. Four patients did not complete treat- 
ment; three of these four patients were enrolled 
during the second month. Two patients died dur- 
ing follow-up. One day after completion of treat- 
ment, nasal carriage had been eradicated in 15 
of 18 patients (83%). Twelve weeks after treat- 
ment, 69% (11 / 16) of the surviving patients were 
free of S. aureus  nasal carriage. Four of the five 
patients had transient loss of nasal carriage but 
reacquired carrier status at the end of follow-up 
period. All five patients who were nasal carriers 
at the end of follow-up did not have diabetes 
mellitus. Only one patient had persistent positive 
groin culture but negative nasal culture. 
Antibiotic susceptibility 
All S. aureus  isolates from pretreatment asal 
cultures were susceptible to oxacillin and all ex- 
cept five isolates were resistant o penicillin. 
These five isolates were also tested for [5-1acta- 
mase production; all were negative. One patient 
was also colonized before treatment with an ox- 
acillin-resistant S. aureus  in the axillae and 
groins. All posttreatment cultures from all sites 
of this patient had no S. aureus .  
In two (50%) of the four isolates from pretreat- 
ment axillary cultures and four (50%) of the eight 
isolates from posttreatment groin cultures, an- 
timicrobial susceptibility was different from that 
of the corresponding isolates from the nasal cul- 
tures of the same patient. In four patients, pre- 
treatment cultures from all three sites were pos- 
itive for S. aureus ,  but in two of these four pa- 
tients the antimicrobial susceptibility of isolates 
from the axillae and groins was different from 
that of the isolate from the anterior nares. 
DISCUSSION 
It has been shown that S. aureus  nasal carriage 
in patients who are undergoing long-term he- 
modialysis is associated with more frequent S. 
aureus  infections and that infections occur less 
frequently in S. aureus  nasal carriers given pe- 
riodic rifampin to eliminate the carrier state7 
However, resistance to rifampin develops fairly 
rapidly. 7In a recent study of oral ciprofloxacin 
plus rifampin in the treatment of patients with 
nasally carried methicillin-resistant S. aureus ,  
resistance to ciprofloxacin also developed rap- 
idly, necessitating the termination ofthe study. 16 
Mupirocin ointment has been used for 9 
months nasally in patients undergoing long-term 
hemodialysis, resulting in the reduction of car- 
riage and infectionY With the long-term usage 
of mupirocin, however, development of resis- 
tance is a real concernY We decided to use short- 
term therapy with mupirocin ointment applied 
intranasally, in conjunction with chlorhexidine 
body scrubs, in an attempt to eradicate S. aureus  
nasal carriage and prevent recolonization of the 
anterior nares from other body sites. 
In this study, we found that the prevalence of
S. aureus  nasal carriage was not higher among 
patients with diabetes mellitus, either insulin- 
dependent diabetes or non-insulin-dependent di- 
abetes, than among patients with no history of 
diabetes mellitus. This is in accordance with 
findings from a large, geographically based 
study.19 Instead, the prevalence ofS. aureus  nasal 
carriage was related to the length of time the 
patient had been undergoing long-term hemo- 
dialysis. The patients who were S. aureus  nasal 
carriers had been undergoing hemodialysis 
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much longer than the ones who were not S. au -  
reus  carriers. This difference almost atta ined sta- 
tistical significance (p = 0.063). 
Our success rates of eradicat ion (83% imme- 
diately after t reatment  and 69% after fol low-up 
for 12 weeks) are excellent, in compar ison with 
other studies of pat ients undergoing hemodi -  
alysis that used topical and oral t reatment  reg- 
imens. 1° In a study using oral and topical anti - 
microbial  agents wi th a 12-week fol low-up pe- 
riod, the rates of eradicat ion of S. aureus  nasal 
carr iage at 12 weeks were 44% and 25%, for 
r i fampin /bac i t rac in  and bacitracin alone, re- 
spectively. 7 With the chlorhexidine body-scrub 
treatment,  axillae and groins were e l iminated as 
sources of nasal recolonizat ion.  We used mupi-  
rocin 2% o intment  in a polyethylene glycol base, 
which is approved by the Food and Drug Ad- 
ministrat ion for topical use on skin surfaces,. Mu- 
pirocin o intment  in a soft paraffin base is cur- 
rently under  cl inical invest igation for intranasal  
use? ° If the efficacy of this short regimen of mu- 
pirocin o intment  and chlorhexidine body scrub 
is conf irmed in large clinical trials, this treat- 
ment  can be used on a periodic basis, perhaps 
every 3 months,  for those patients who are 
S. aureus  nasal carr iers by repeated cultures. 
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